Recently, IgA mAbs targeting tumor cells such as HER2 (mammary carcinoma) and CD20 (B‐cell lymphoma) have shown promising antitumor effects.46 Interestingly, the use of FcαRI transgenic mouse models has shown that IgA2 anti‐EGFR antibodies can induce tumor cell killing, most likely mediated by macrophages.3 However, more in vivo work is needed to dissect the contribution of FcαRI‐expressing effector cells in tumor killing. This evidence concerns the gene EGFR and neoplasm.